Amgen’s Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 Amgen reported adjusted earnings per share of $1 aygestin.org .29 for the next quarter of 2009, an increase of 13 % in comparison to $1.14 for the second quarter of 2008. Altered net income elevated 6 % to $1,311 million in the second quarter of 2009 in comparison to $1,235 million in the next one fourth of 2008. Total revenue decreased 1 % through the second one fourth of 2009 to $3,713 million versus $3,764 million in the next quarter of 2008. We are optimistic about our financial performance in ’09 2009 and are focused on making denosumab successful, stated Kevin Sharer, chairman and chief executive officer.
Meals and Medication Administration accepted twice-weekly administration schedule in individuals with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent . The trial was initiated predicated on results from the Phase 1/2 CHAMPION study, that have been presented at the 51st Annual Achieving of the American Culture of Scientific Oncology on Sunday, May 31 at 8 a.m. CT. Outcomes from the Phase 1 and 2 portions of CHAMPION were presented for 104 patients with relapsed or refractory multiple myeloma who had received someone to three prior treatment regimens at the identified maximum tolerated dosage of 20/70 mg/m2.